Anthropometric characteristics at birth and growth outcome in patients with X-linked hypophosphatemia treated with oral phosphate and active vitamin D.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this observational study publication.

X-linked hypophosphatemia (XLH) is the most common form of inherited rickets, resulting in short stature despite treatment with oral phosphate and active vitamin D.

Detailed data of anthropometric parameters at birth, during infancy, and on the influence of an affected parent on outcome are lacking.

Who Took Part

The study group was 198 children.

PubMed indexes the participants as infants, young children, children and teenagers, both men and women.

In this prospective multicenter observational study, conducted from 1998 to 2023 in Germany, Austria, and Switzerland, body length, body weight, and head circumference were investigated in 198 children with XLH from birth until the age of 18 years, all being only on supplementation therapy.

How the Study Was Run

In design terms this was a multicenter study.

More than one site took part, so the children came from several places.

What Was Measured

Detailed data of anthropometric parameters at birth, during infancy, and on the influence of an affected parent on outcome are lacking.

Topics PubMed links to this paper include Familial Hypophosphatemic Rickets, Phosphates, Body Height, Anthropometry, Vitamin D, Infant, Small for Gestational Age and Birth Weight.

Author keywords: Alkaline phosphatase, Birth anthropometry, Body disproportion, Growth, Hypophosphatemia and XLH.

What This Means in Plain Language

The paper is a multicenter study of Vitamin D, K2, Magnesium and Zinc in 198 children.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Pediatric nephrology (Berlin, Germany)), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.